1A. In patients with stable cirrhosis undergoing common gastrointestinal procedures, AGA makes no recommendation regarding visco-elastic testing (VET) before procedures to predict bleeding risk.
1B. In patients with stable cirrhosis (with known baseline abnormal coagulation parameters) undergoing common gastrointestinal procedures (e.g., paracentesis, thoracentesis, variceal banding, colonic polypectomy, ERCP and liver biopsy), AGA suggests against the use of extensive preprocedural testing, including repeated measurements of prothrombin time/international normalized ratio (PT/INR) or platelet (PLT) count.
2A. In patients with stable cirrhosis undergoing common gastrointestinal procedures (e.g., paracentesis, thoracentesis, variceal banding, colonic polypectomy, ERCP and liver biopsy), AGA suggests against the routine use of blood products (e.g., FFP and PLT) for bleeding prophylaxis.
2B. In patients with thrombocytopenia and stable cirrhosis undergoing common procedures (and in particular, “low-risk” procedures), AGA suggests against the routine use of TPO-RAs for bleeding prophylaxis.
3. In hospitalized patients with cirrhosis and who otherwise meet standard guidelines for the use of venous thromboembolism (VTE) prophylaxis, AGA suggests standard anticoagulation prophylaxis over no anticoagulation.
4. In patients with cirrhosis, AGA suggests against routine screening for portal vein thrombosis (PVT).
5. In patients with cirrhosis and acute or subacute nontumoral PVT, AGA suggests using anticoagulation over no anticoagulation for treatment of PVT.
6. In patients with cirrhosis and atrial fibrillation with an indication for anticoagulation, AGA suggests using anticoagulation over no anticoagulation.
